We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+37.8%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$198M
AUM Growth
+$69.6M
Cap. Flow
+$26.9M
Cap. Flow %
13.6%
Top 10 Hldgs %
58.47%
Holding
43
New
13
Increased
10
Reduced
5
Closed
6

Top Buys

Rank Stock Value
1
KYNB
Kyntra Bio
KYNB
+$4.93M
2
ARAV
Aravive, Inc. Common Stock
ARAV
+$4.58M
3
GNMX
Aevi Genomic Medicine Inc
GNMX
+$4.2M
4
KITE
Kite Pharma, Inc.
KITE
+$3.2M
5
SUPN icon
Supernus Pharmaceuticals
SUPN
+$2.94M

Top Sells

Rank Stock Value
1
NSPR icon
InspireMD
NSPR
+$4.59M
2
BIND
BIND THERAPEUTICS INC
BIND
+$3.87M
3
PRTA icon
Prothena Corp
PRTA
+$3.48M
4
GNMK
GenMark Diagnostics, Inc
GNMK
+$2.4M
5
AEGR
Aegerion Pharmaceuticals
AEGR
+$1.92M

Sector Composition

Rank Sector Weight
1 Healthcare 91.91%
2 Miscellaneous 8.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CPRX
26
DELISTED
Catalyst Pharmaceutical
CPRX
$2.9M 1.46%
975,000
– –
HZNP
27
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$2.84M 1.43%
+220,000
New +$2.75M
ALNY icon
28
Alnylam Pharmaceuticals
ALNY
$31.7B
$2.82M 1.43%
29,100
– –
AXDX
29
DELISTED
Accelerate Diagnostics
AXDX
$1.92M 0.97%
10,000
+1,080
+12% +$231K
CELGZ
30
DELISTED
Celgene Corporation Contingent Value Rights
CELGZ
$1.81M 0.92%
575,000
-85,000
-13% -$287K
TENX icon
31
Tenax Therapeutics
TENX
$82M
$1.69M 0.85%
+14
New +$1.69M
EVOK
32
DELISTED
Evoke Pharma
EVOK
$1.42M 0.72%
1,667
-187
-10% -$154K
NBIX icon
33
Neurocrine Biosciences
NBIX
$15.8B
$1M 0.51%
+45,000
New +$853K
TVRD
34
Tvardi Therapeutics
TVRD
$24M
$798K 0.4%
+2,222
New +$716K
BLRX
35
BioLineRX
BLRX
$12.1M
$405K 0.2%
417
-400
-49% -$348K
NSPR icon
36
InspireMD
NSPR
$41.6M
– –
0
– -$4.59M
PRTA icon
37
Prothena Corp
PRTA
$467M
– –
-157,000
Closed -$3.48M
DRNA
38
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-134,500
Closed -$1.71M
AEGR
39
DELISTED
Aegerion Pharmaceuticals
AEGR
– –
-57,500
Closed -$1.92M
CPXX
40
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
– –
-405,000
Closed -$1.02M
KIPS
41
DELISTED
KIPS BAY MEDICAL INC
KIPS
– –
-50,000
Closed -$8.51K
BIND
42
DELISTED
BIND THERAPEUTICS INC
BIND
– –
-450,000
Closed -$3.87M
1
2

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q4 2014 Portfolio in Review

As of Q4 2014, Opaleye Management held 43 positions worth $198M, up 54% from $128M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Opaleye Management deployed $26.9M of net new capital in Q4 2014, opening 13 new positions and adding to 10 existing holdings. Its largest new stake was Kyntra Bio: 7,654 shares worth $5.23M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 87% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was GenMark Diagnostics, Inc, an estimated $2.4M trimmed.

  • Opaleye Management's largest Q4 2014 buy was Kyntra Bio: 7,654 shares worth $5.23M.
  • Opaleye Management added most to Geron in Q4 2014, an estimated $2.78M increase.
  • Opaleye Management's biggest Q4 2014 reduction was GenMark Diagnostics, Inc, cutting an estimated $2.4M.
  • Opaleye Management fully exited BIND THERAPEUTICS INC in Q4 2014, selling an estimated $3.87M.
  • Opaleye Management's ten largest holdings make up 58% of its $198M portfolio in Q4 2014.
  • Opaleye Management opened 13 new positions and closed 6 in Q4 2014.
  • Opaleye Management's portfolio value rose 54% quarter-over-quarter to $198M.

Based on Opaleye Management's 13F filing for Q4 2014, filed 13 Feb 2015.